At a glance
- Nafarelin is an FDA-approved drug, marketed as Synarel (first approval: February 13, 1990).
- PubMed lists 274 publications mentioning it, including 59 randomized controlled trials and 28 animal-only studies.
- ClinicalTrials.gov lists 12 registered studies testing it (4 active).
- FDA's adverse event system (FAERS) holds 304 reports mentioning it; 256 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA019886 | SYNAREL | Approved, marketed | February 13, 1990 | PFIZER |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?
- Trends in endometriosis interventions: an interrupted time series analysis following the Australian National Action Plan for Endometriosis (NAPE) 2018.
- A study on the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy for uterine fibroids and adenomyosis.
- Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation.
- Anti-Dengue: A Machine Learning-Assisted Prediction of Small Molecule Antivirals against Dengue Virus and Implications in Drug Repurposing.
- Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.
- Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?
- In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.
- Gonadotropin-Releasing Hormone (GnRH) Agonist Implants for Male Dog Fertility Suppression: A Review of Mode of Action, Efficacy, Safety, and Uses.
- "Flexible-Acceptor" General Solubility Equation for beyond Rule of 5 Drugs.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 12
- Active
- 4
- With posted results
- 0
Conditions studied
Show 2 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| Short Versus Long Protocol for IVF and IVF+ICSI | Completed | Phase 4 | Jan 2009 |
| Endometriosis : Traditional Medicine vs Hormone Therapy | Completed | Phase 1, Phase 2 | Sep 2002 |
All 12 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 304
- Serious
- 256
- With death outcome
- 11
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.